Transgenic animals expressing human p25
AssigneePfizer Inc.
InventorsJohn D. McNeish, Michael K. Ahlijanian
Life of this patent
Estimating the term…
Loading patent…
AssigneePfizer Inc.
InventorsJohn D. McNeish, Michael K. Ahlijanian
Estimating the term…
The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 (activator of the protein kinase cdk 5) polypeptide. The two neuropathological lesions associated with Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles (NFTs), composed predominantly of amyloid β peptides and hyperphosphorylated tau, respectively. While animal models for plaque formation exist, there is no animal model that recapitulates the formation of NFTs. This invention provides transgenic mice that overexpress human p25, an activator of cdk5, resulting in tau that is hyperphosphorylated at AD-relevant epitopes. Deposition of tau is detected in the amygdala, thalamus and cortex. Increased phosphorylated neurofilament, silver-positive neurons and neuronal death are also observed in these regions. We conclude that the overexpression of p25, an activator of cdk5, is sufficient to produce hyperphosphorylation of tau and neuronal death. The p25 transgenic mouse represents the first model for tau pathology in AD.
Recombinant DNA comprising a rat neuron specific enolase promoter operably linked to a p25 encoding sequence of the human cdk5 gene encoding sequence.
A method for treating an animal having a disease characterized by the expression of a p25 fragment of a human cdK5 gene comprising administering a therapeutically effective amount of an inhibitor of said p25 fragment.
Dependencies are inferred from the claim text.